US Stock MarketDetailed Quotes

TRAW Traws Pharma

Watchlist
  • 5.020
  • -0.315-5.90%
Close Dec 20 16:00 ET
  • 5.120
  • +0.100+1.99%
Post 17:05 ET
15.19MMarket Cap-0.04P/E (TTM)
Post-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Oct 10 12:29
    NEWS
    $Traws Pharma (TRAW.US)$
    Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment
    Expert Systems celebrates a milestone in the clinical development of tivoxavir marboxil, a potential one-time influenza treatment. Developed by Traws Pharma(NASDAQ: TRAW), tivoxavir showed positive topline Phase 1 safety and pharmacokinetic results, supporting its potential as a broad-spectrum flu treatment.
    Expert Systems' AI-enabled drug discove...
    Trytosaveabit
    Trytosaveabit
    Oct 8 06:32
    Update
    $Traws Pharma (TRAW.US)$ Reuters· 1 min ago
    Traws Pharma Inc - Preclinical Data Show Potent Inhibition of Drug-Resistant and Bird Flu Viruses
    Jaguar8
    Jaguar8
    Oct 8 06:31
    NEWS
    $Traws Pharma (TRAW.US)$
    Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
    Traws Pharma (NASDAQ: TRAW) announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza therapy, tivoxavir marboxil. The study demonstrated good overall tolerabilityand a pharmacokinetic profile supporting potential use as a one-time treatment for flu, including pandemic flu. Key findings include:
    1. A single dose maintained ...
    Jaguar8
    Jaguar8
    Sep 30 07:06
    NEWS
    $Traws Pharma (TRAW.US)$
    Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
    Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
    Phase 2a study expected to begin in H1 2025 in patients with COVID
    Improving COVID care is an ongoing need, with approximately 50,000 US deaths in 2023
    NEWTOWN, Pa., Sept. 30, 2024 (GLOB...
    Trytosaveabit
    Trytosaveabit
    Sep 30 06:32
    Update
    $Traws Pharma (TRAW.US)$ Reuters
    1 min ago
    Traws Pharma Announces Positive Topline Phase 1 Results for Covid Candidate, Ratutrelvir, an Oral Mpro Inhibitor
    Traws Pharma Inc - Ratutrelvir Well-Tolerated, Achieved Consistent Plasma Levels Without Ritonavir
Read more
Heat List
US
Overall
Symbol
Price
% Chg

No Data